Search

Displaying results 371 - 380 of 3917 in total
  1. Drug

    Ansuvimab

    go.drugbank.com/drugs/DB16385
    Approved

    [A207646] Ansuvimab received FDA approval on December 21, 2020, and is currently marketed as Ebanga by Ridgeback Biotherapeutics, LP. Ansuvimab is just the second FDA-approved treatment for EVD.

  2. Drug

    Sodium chloride

    go.drugbank.com/drugs/DB09153
    ApprovedInvestigationalVet approved

    It is listed on the World Health Organization Model List of Essential Medicines.

    Mixtures: Prismasol BO, PRISMASOL BO SOLUTION
  3. Drug

    Finerenone

    go.drugbank.com/drugs/DB16165
    ApprovedInvestigational

    [A236544,L34739] Finerenone was granted FDA approval on 9 July 2021,[L34739] followed by the EMA approval on 11 March 2022.[L41449]

  4. Drug

    Apomorphine

    go.drugbank.com/drugs/DB00714
    ApprovedInvestigational

    [A203597,A203618] Apomorphine was granted FDA approval on 20 April 2004.[L13919] … Apomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884.

  5. Drug

    Daclizumab

    go.drugbank.com/drugs/DB00111
    ApprovedInvestigationalWithdrawn

    2 March 2018 [L1738]. … approved for use, Zinbryta (daclizumab)'s complex pre-existing safety profile consisting of its restricted availability through a Risk Evaluation and Mitigation Strategy program [L1738] and its black box

  6. Drug

    Toremifene

    go.drugbank.com/drugs/DB00539
    ApprovedInvestigational

    [A256928] Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however … , it also has antiestrogenic (estrogen-antagonist) activity on breast tissue.

    Categories: Bone Density Conservation Agents
  7. Drug

    Isavuconazonium

    go.drugbank.com/drugs/DB06636
    ApprovedInvestigational

    Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis … [A6913,A6914,A262706] On December 08, 2023, the FDA approved the expanded use of isovuconazonium in pediatric patients for the same indications.[L49251]

  8. Drug

    Human Rho(D) immune globulin

    go.drugbank.com/drugs/DB11597
    Approved

    Immune globullin was purified via ion-exchange chromatography method and prepared from pools of human plasma, where the donors are Rho (D)-negative donors who have been immunized with Rho(D)-positive RBCs

  9. Drug

    Pinaverium

    go.drugbank.com/drugs/DB09090
    ApprovedInvestigational

    Pinaverium is a spasmolytic agent used for functional gastrointestinal disorders. It is a quaternary ammonium compound that acts as an atypical calcium antagonist to restore normal bowel function. It is shown to relieve GI spasm and pain...

    Mixtures: DISPAX ® CAPSULAS DURAS CON CONTENIDO LIQUIDO
  10. Drug

    Nabumetone

    go.drugbank.com/drugs/DB00461
    Approved

    Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).

    Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-Narcotic